Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 402
Montréal, Québec CA H4M 2X6

  

VIA EDGAR

 

October 1, 2021

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Christopher Edwards

 

Re:	Milestone Pharmaceuticals Inc.
	Registration Statement on Form S-3 Filed June 25, 2021
	File No. 333-257404
	Acceleration Request
	Requested Date:	Tuesday, October 5, 2021
	Requested Time:	4:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257404) (the “Registration Statement”) to become effective on Tuesday, October 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

 

The Registrant hereby authorizes each of Marc Recht, Ryan Sansom and Layne Jacobs of Cooley LLP to make such request on its behalf.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Layne Jacobs of Cooley LLP, counsel to the undersigned registrant, at (617) 937-2321.

  

[Signature Page Follows]

 

 

Sincerely,
Milestone Pharmaceuticals Inc.
By:	/s/ Joseph Oliveto
	Joseph Oliveto
	Chief Executive Officer

  

cc:	Amit Hasija, Milestone Pharmaceuticals Inc. Ryan Sansom, Cooley LLP Layne Jacobs, Cooley LLP